Pernix Therapeutics announced that they expect to resume distribution of the 20mg dosage strength of Zohydro ER (hydrocodone bitartrate) with BeadTek on March 28, 2018 after a manufacturing issue last May resulted in the product being on back order.
Zohydro ER, a Schedule II substance, is indicated for the management of pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatment (eg, non-opioid analgesics or immediate-release opioids) are inadequate.
“This (20mg) dosage strength provides healthcare professionals with another option when transitioning patients impacted by chronic pain from an immediate release form of hydrocodone,” said John Sedor, Pernix’s Chairman and CEO.
Zohydro ER is also available in 10mg, 15mg, 30mg, 40mg, and 50mg dosage strengths.
For more information visit Pernix.com.
This article originally appeared on MPR